Antibiotic duration and changes in FEV(1) are not associated with time until next exacerbation in adult cystic fibrosis: a single center study

BACKGROUND: Pulmonary exacerbations (PEx) are a major driver of morbidity and mortality in cystic fibrosis and reducing their frequency by extending the time between them is an important therapeutic goal. Although treatment decisions for exacerbations are often made based on dynamic changes in lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Espel, Julia C., Palac, Hannah L., Cullina, Joanne F., Clarke, Alexandria P., McColley, Susanna A., Prickett, Michelle H., Jain, Manu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707785/
https://www.ncbi.nlm.nih.gov/pubmed/29187171
http://dx.doi.org/10.1186/s12890-017-0503-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707785/
https://www.ncbi.nlm.nih.gov/pubmed/29187171
http://dx.doi.org/10.1186/s12890-017-0503-6

Ejemplares similares